Pharmacokinetics.
SAD
Pharmacokinetic outcomes for the individual cohorts in the SAD study are presented in OPC-167832 pharmacokinetics. (A and B) Mean plasma concentration versus time in healthy adult participants following single administrations of OPC-167832. (C and D) Mean plasma concentration versus time in healthy adult participants following a single 60-mg dose of OPC-167832 administered after a standard meal, fasting or a high-fat meal. (E and F) Mean plasma concentrations of OPC-167832 versus time at steady state (day 14) following once-daily administrations of OPC-167832 in patients with rifampicin- and isoniazid-susceptible pulmonary TB. A, C, and E present the data on semilogarithmic plots. B, D, and F present the data on linear plots. Time points beyond 24 h are not presented in B, D, and F to clearly distinguish early time points. Error bars are ± SD.Dose proportionality of OPC-167832. AUCSingle dose pharmacokinetic parameters of OPC-167832Values are mean ± standard deviation, unless noted. AUCPharmacokinetic outcomes for the individual cohorts in the MAD study are presented in Multiple dose pharmacokinetics of OPC-167832Values are mean ± standard deviation, unless noted.